Wall Street brokerages forecast that TG Therapeutics Inc (NASDAQ:TGTX) will post sales of $40,000.00 for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for TG Therapeutics’ earnings. TG Therapeutics also posted sales of $40,000.00 during the same quarter last year. The business is expected to announce its next earnings report on Friday, March 9th.
On average, analysts expect that TG Therapeutics will report full-year sales of $40,000.00 for the current financial year, with estimates ranging from $150,000.00 to $200,000.00. For the next year, analysts anticipate that the company will report sales of $150,000.00 per share, with estimates ranging from $150,000.00 to $160,000.00. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.05). The company had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative net margin of 82,770.73% and a negative return on equity of 160.60%.
Shares of TG Therapeutics (NASDAQ TGTX) opened at $9.35 on Friday. The stock has a market cap of $660.60, a PE ratio of -4.84 and a beta of 1.30. TG Therapeutics has a 52-week low of $4.10 and a 52-week high of $15.35.
In other news, CFO Sean A. Power sold 32,006 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total value of $272,051.00. Following the completion of the sale, the chief financial officer now owns 517,464 shares in the company, valued at approximately $4,398,444. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 16.70% of the company’s stock.
Several large investors have recently bought and sold shares of TGTX. State Street Corp raised its stake in shares of TG Therapeutics by 274.4% during the 2nd quarter. State Street Corp now owns 2,638,683 shares of the biopharmaceutical company’s stock worth $26,515,000 after acquiring an additional 1,933,896 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of TG Therapeutics by 14.3% during the 2nd quarter. Vanguard Group Inc. now owns 2,046,427 shares of the biopharmaceutical company’s stock worth $20,566,000 after acquiring an additional 255,844 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of TG Therapeutics by 150.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 277,235 shares of the biopharmaceutical company’s stock worth $2,786,000 after acquiring an additional 166,434 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of TG Therapeutics by 176.8% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 243,485 shares of the biopharmaceutical company’s stock worth $2,886,000 after acquiring an additional 155,535 shares in the last quarter. Finally, Columbus Circle Investors raised its stake in shares of TG Therapeutics by 9.8% during the 3rd quarter. Columbus Circle Investors now owns 1,532,911 shares of the biopharmaceutical company’s stock worth $18,165,000 after acquiring an additional 136,515 shares in the last quarter. Institutional investors and hedge funds own 50.41% of the company’s stock.
TRADEMARK VIOLATION WARNING: “TG Therapeutics Inc (TGTX) Expected to Announce Quarterly Sales of $40,000.00” was first posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/01/20/tg-therapeutics-inc-tgtx-expected-to-announce-quarterly-sales-of-40000-00-2.html.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.